CLICK AICI pentru limba ROmana(traducerea „aproximativa” utilizand google translate).
For those of you still interested in an more effective form of chemotherapy (about 10 times more effective), safer – using less chemo drugs(about 10 times the standard chemo doze) thus, without the major side effects of chemotherapy here is an article about IPT(Insulin Potentiation Therapy), a technique that gets chemo drugs directly into cancer cells ( about 10 times more inside cancer cells than in normal cells,to be more specific) .
Though IPT is not detailed in my book, I’ ve contacted Annie Brandt , Founder & Executive Director ,BEst Answer for Cancer Foundation , „Thriving While Surviving” , A Whole-Being Healing Platform + Targeted Cancer Therapies = Integrative Oncology , www.bestanswerforcancer.org and http://www.iptforcancer.com/ and am waiting for their review and updates as well (as mentioned in previousposts, I am alos waiting for reviews and updates from the Gerson Institute – run by Charlotte Gerson , daughter of Dr. Gerson , The Metabolic Institute – coordinated by the son of l Dr William Kelley , Issels clinic – coordinated by wife of Dr Iosef Issels, Hope4Cancer clinic ICRF Inc, cancertutor and others.I’ll let you know about the institutes centers and clinics this site officially endorses and is endorsed by officially ( mutual support including and exchangeof knowledge and experience)
IPT is insulin potentiation therapy, a non-diabetic use of the hormone insulin to dramatically improve effectiveness and delivery of standard medications.
Breakthrough results have also been reported for arthritis, as well as for infectious, respiratory, cardiovascular, neurological, and other diseases.
This slight modification of standard medicine could help many medications act like super drugs, with better results for many millions of patients. The US National Institutes of Health has expressed interest in clinical trials of IPT for cancer, but has so far provided no funding.
IPT is 21st century medicine. Discovered in 1926 by Donato Perez Garcia MD, fostered by his son and grandson, with 140+ doctor-years of experience over 72 years, yet still unknown by the world, IPT is just starting a scientific and clinical rebirth.
IPT = Insulin Potentiation Therapy
„The second discovery of insulin” ™
Chinese lab data published Feb. 2003 show that insulin significantly increases tumor cell killing effect of three chemotherapy drugs on esophageal and lung cancer cell lines.
IPT doctors are now listed on
Historic 1976 IPT paper now available on IPTQ.com. (10/19/03)
„Treating Cancer with IPT”,
Cellular Therapy, a historical book by Donato Perez Garcia (1), in a new English translation by Aime Ricci, is now available publicly for the first time, on IPTQ.com.
IPT training for physicians is available now, in a workshop in the US, or privately in the clinics of Dr. Perez Garcia or Dr. SGA.
IPT is available now from
IPT presented to the US NIHseveral times, but so far without results.
Six books about IPT, an IPTQ exclusive.
Interview with Donato Perez Garcia MD 3.
Letters about IPT to and from public figures.
What people have said about IPT:
„I feel like I am the recipient of a miracle. I feel a gratitude that words will never express.” – former IPT patient Donna McDermott .
„IPT needs to be the treatment of choice with chemo. There should be no question about that. For everyone, especially children, the risks and side effects are so much less than with regular administration of chemo.” – Susan Holder, nurse and mother of a child with cancer.
„I am honored to be an instructor in IPT and must thank you again and again for not only changing my life but life of all my past, present and future patients…you [Dr. Donato Perez Garcia] and your father and grandfather are great men, there is no doubt.”
„Medicine of Hope” – JC Paquette MD
„Your ideas about making standard drugs work better are interesting….” – former US President Bill Clinton
„IPT is a weapon of mass benevolence.”
Cancer and IPT
IPTLD: Targeting the Cancer Cells… Not the Patient!™
Insulin Potentiation Targeted Low Dose therapy (IPTLD) is a procedure for targeting chemotherapeutic drugs directly to cancer cells, making the drugs tougher on the disease and easier on the rest of the body.
Conventional chemotherapy tends to flood the body with drugs so enough will enter the cancer cells to kill them. Each of our trillions of cells has a membrane, an outer skin, that protects it from toxins. Standard chemotherapy must be given in large enough quantities to force penetration through that membrane.
IPTLD, however, penetrates easily through the cell membrane because it goes in hand-in-hand with sugar (glucose). Cancer cells, unlike healthy cells, need lots of glucose for fuel. Without it, they die. The membrane of a cancer cell is designed to take in a lot more glucose than healthy cells. In medical parlance we say cancer cells are equipped with many more insulin receptors. So, what if we pair a small dose of chemo drugs with the glucose? Yes, the cancer cell takes in the chemotherapy drugs in its effort to get at the sugar. Using insulin allows us to differentiate the cancer cells from the normal cells. This is a significant advantage.
How does IPT actually work?
When a doctor administers IPTLD, the first thing he or she does is to gently lower the patient’s blood sugar level with insulin, the same natural hormone diabetics use. The cancer cells, because they must have sugar to live, become ravenous and open those insulin receptors wide to get at whatever they can find in the blood stream’s diminishing supply. When the blood sugar level has dropped enough, the doctor will administer a low dose of chemotherapy. The cancer cells take it in. The doctor then administers glucose which brings the patient’s blood sugar level back up to normal.
Because insulin assists in the delivery of the drugs, IPTLD uses about 90% less chemotherapy compared to conventional oncology. This means that patients continue to thrive, maintain their lifestyle, and be vital while the cancer is eradicated.
Insulin helps us in another way. Chemo is most effective when it connects with a cancer cell as it is dividing because cells are most vulnerable at that phase in their life cycle. Insulin prompts cancer cells to divide – it is thought that insulin is able to prompt cell division at what is called the “therapeutic moment,” the moment when the doctor determines the blood sugar level has dropped enough and the chemotherapy is administered. Thus, insulin helps us deliver chemo when more cells are most vulnerable.
The cells that turn over the fastest in the human body – the ones most likely to be dividing at any one time – are in the intestine, in our mouths, and hair follicles. That is why the side effects with conventional chemo cause people to go bald and often lead to mouth and stomach ulcers, and organ failure. Without insulin, the conventional large dose of chemotherapy attacks whatever cancer cells happen to be dividing, plus the other rapidly dividing cells in the body of which there are many.
What are the benefits of IPTLD?
- IPTLD can be very tough on tumors while being very gentle for the patient who continues to live a normal, vital lifestyle while being treated.
- Using insulin allows us to differentiate the cancer cell population from the normal cell population. That means a lower dose of chemotherapy can be used and this is important since these drugs have considerable toxicity associated with them.
- IPTLD reduces chemotherapy side effects in normal cells.
- IPTLD enhances chemotherapy’s killing effectiveness in cancer cells. A 1981 study found that using insulin increased the killing effect of the chemo drug methotrexate by a factor of 10,000, for example.
- Gentle treatment and the use of complementary therapies to strengthen the immune system is our body’s best natural defense against the return of cancer. View additionalComplementary Therapies.
- IPTLD treatments cost significantly less than conventional chemo.
STANDARD CHEMOTHERAPY VS. IPT LowDose
Effect Standard Chemotherapy IPTLD Aggressively kills cancer Y Y Hair Loss Y Mild or none Nausea Y Mild or none Loss of Appetite/Anorexia Y Mild or none Diarrhea Y N Reproductive Organs Effected/Sterility Y N Ultimate Increase of MDM2 Leading to Depletion of p53 Gene Y N Immune System is Damaged Y N Cancer is strengthened Y N Severe Physical & Mental Fatigue Y N Healthy Cells DNA Distortion Making Y N Them Pre-Cancerous Y N Thrombocytopenia Y N Anemia Y Mild or none Infections Y Mild or none Neutropenia Y N Emotional Side Effects Y N Chemo Brain side effect Y N
What cancers respond to IPTLD?
IPTLD has been reported to work especially well for breast, prostate, lung, colon, stomach cancers, lymphoma, and melanoma. There are also reports of IPTLD bringing responses and remissions to patients with some very difficult cancers, including pancreatic, ovarian, and renal cell cancers. Other cancers successfully treated are blood, bone, cervical, esophageal, lip, mouth, neck, small intestines, testicular, throat, thyroid, uterine and vaginal.
Why doesn’t my regular oncologist use IPTLD?
IPTLD uses only about 10% to 15% of the pharmaceutical drugs used in traditional chemotherapy. Understandably, the pharmaceutical industry has been slow to encourage doctors to use less of their product. Medical school curriculum is still focused on insulin’s use in diabetes.
Credit for the discovery of insulin in 1921 goes to Dr. Frederick Banting, a Canadian surgeon. In the early 1930s, Dr. Donato Perez Garcia, a Mexican surgeon, discovered that giving insulin to a patient would allow more antibiotic drugs to penetrate the blood brain barrier. In the 1940s, he discovered that the same technique would allow more chemotherapeutic drugs to enter cancer cells, thus opening the way for targeted chemotherapeutic treatments that do not damage nearly as many healthy cells.
IPTLD has been used for cancer worldwide since 1946; it has been used in the United States since 1997.
View PDF: How I Deal With My Cancer? By Dr. Donato Perez Garcia
NOTE: The Best Answer for Cancer Foundation is not, in any way, associated with Dr. Donato Perez Garcia.
Alabaster, A; Vonderhaar, B; Shafie S. Metabolic modification by insulin enhances methotrexate cytotoxicity in MCF-7 human breast cancer cells. Eur J Cancer Clin Oncol. 17:1223-1228
Rewriting the Book of Oncology ™
„I treat patients; I do not treat cancer.” – Dr. Perez Garcia 3
|Joy, not despair
Safe-trial (trying IPT first)
Viral or bacterial origin?
Research is needed
Let’s get serious
Specific kinds of cancer
Cancer is one of the most successful applications of insulin potentiation therapy (IPT). This method was first used to treat cancer in 1945, by Dr. Perez Garcia 1, and has been used with very good results by all the IPT doctors since.
The treatment of cancer patients with IPT is, it appears, harmless at worst, and spectacular at best. If cancer is caught early enough (which can be rather advanced), and if there is a chemotherapy drug or combination that has been found effective, complete remission with IPT is a very common occurrence. And all this without surgery, radiation, or major side effects. IPT cancer patients often feel (and look) better from the first treatment on, and often appear lively and enthusiastic. Even if IPT does not achieve complete remission, it generally helps relieve symptoms and pain, and improves quality of life for the days that remain to the patient. And at worst, reminiscent of of the Hippocratic Oath, it does no harm.
Once when I was visiting Dr. Perez Garcia 3 in his office, he showed me a follow-up CAT scan of one of his cancer patients, now in complete remission. Although there was absolutely no trace of tumors on the images, the radiologist, knowing the patient’s history, had apparently felt obliged to write that the tumors were now „almost invisible”. Donato laughed, „Yes, I am the doctor who can make your tumors ‘almost invisible’ … for the rest of your life!”
Wouldn’t every oncologist in the world like to have a tool that would allow him to joke with such joy?
Instead, oncology today offers a great deal of hope, but only after guiding the patient through a grim battlefield of mutilation (surgery), burning (radiation), and/or poisoning („normal” or high dose chemotherapy). Grim side effects are accepted as common, likely, often inevitable, and are dealt with as well as possible: surgical scars and adhesions, hair loss, weight loss, nausea, sterility, immune system depression, and secondary infections. Survival for five years is considered a „cure”, no matter how much damage has been done to the patient’s general health. And the sad reality is that a large fraction of patients who die of cancer „complications” actually die from the side effects of treatment. (My own father certainly did.)
No wonder a new diagnosis of cancer is usually such a big shock to a patient. Cancer diagnosis often triggers strong negative reactions in many people: shame, horror, fatalism. IPT could provide new hope. If cancer is detected early, the IPT protocol appears to offer a good chance for complete remission without major negative side effects.
It seems almost too easy. My guess is that, even after IPT becomes proven, there will still be people who choose the former standard methods, under the misimpression that more suffering will bring better results. But the majority of patients will be overjoyed to go with a gentler, safer therapy.
While no statistics have been reported for IPT success rates for various cancer types, here is a rough estimate given by Dr. Perez Garcia 3 in an email, based on his years of experience. To summarize:
For tumor less than 4 cm, and no other therapies (chemo, radiation) have been used:
full remission rate 95%.
For tumor greater than 4 cm, and no other therapies used:
full remission rate 80%.
For recurrence/metastasis after other therapies were used:
full remission rate 25%, partial remission rate 70%, quality of life improvement 98%.
For terminally ill patients, with no liver impairment:
quality of life improvement 40%.
For brain tumor smaller than 2 cm, with no other therapies used:
tumor shrinkage response rate is 65%.
Again, these are rough estimates by just one doctor, based on his experience, and should not be used as if they were accurate.
Drs. Perez Garcia 1 and 2, in their work with the Oncodiagnosticator, a simple electrochemical blood analysis method, thought that they were able to detect cancer in its earliest stages, and even pre-cancerous conditions. Whether or not their observations are corroborated, it opens the imagination to a whole new system in which minimally invasive testing can detect pre-cancer or earliest stage cancer, and a few gentle IPT treatments can restore health, as verified again by more testing. A small preliminary study by SGA MD, at McGill University in 1975, found no predictive value. But the method has not, to my knowledge, been tested in any other laboratory.
In the mean time, there is nothing to stop any doctor from treating his cancer patients with the IPT protocol right now. It calls for exactly the same government-approved chemotherapy drugs, only in doses about 10 percent of normal. And it uses a commonly available hormone, insulin, as a biological response modifier. I am convinced that the only reason more doctors aren’t using it now is that they don’t know about it yet.
SGA MD has suggested that, in cases of cancer types that have a history of success with IPT, physicians should consider an IPT „safe-trial” period of about a month. IPT would be tried first. If rapid progress is observed, IPT would continue. If IPT is not working, the patient could then go on to a program of today’s standard treatments.
How can IPT achieve such superb reported results, yet with small fractional doses of IPT? We have our theories. You can read a summary on the How IPT Works page. And for more detailed discussion, see the patents, articles, and protocols by Dr. SGA and the Drs. Perez Garcia.
There appear to be several predominant mechanisms at work:
1. Insulin makes cell membranes more permeable,
so drugs can be transported and delivered more effectively.
2. There are many more insulin receptors on typical cancer cells,
so more drug concentration is delivered to them.
3. Insulin stimulates cancer cells to begin to divide, making them
more vulnerable to many chemotherapy drugs.
4. Possible stimulation of immune function and elimination of toxins.
5. Poorly-understood improvements of blood chemistry that favor healing
and discourage cancer.
IPT for cancer can be seen simply as chemotherapy, but a more refined style of chemotherapy. Dr. Paquette liked to use a Latin motto to describe IPT: Non nova sed nove – „nothing new, but in a new way”.
The same injection and IV supplies are used. And the same drugs are used; but the biological response of the body is modified to make them much more effective in much smaller, much less toxic doses. Effectiveness is reported to be so great that IPT can be used as a primary treatment, without the need for surgery and radiation.
This whole idea of IPT may seem so radical to some doctors that they may have a hard time taking the leap of faith needed to try it, even for a brief „safe-trial” period. But, based on the experience of other doctors, once they do, they will be very happy with the results. IPT, when verified, could truly be the fulfillment of chemotherapy.
So many cancer patients undergoing standard treatment look weak and malnourished, despite efforts to take supplements and eat a good diet. This can be partly due to the nausea and lack of appetite resulting from standard treatment (anorexia), and partly due to metabolic effects of the cancer itself (cachexia). Weight loss can be severe, and is responsible for much of the morbidity and mortality among cancer patients.
IPT avoids the nausea, and in fact stimulates a hearty appetite in patients. It also facilitates the rapid absorption into the body of intravenous nutrients given during the IPT treatment, and of food after the IPT treatment. See Kabadi UM et al, AIDS Patient Care STDS 2000 Nov;14(11):575-9, „Weight gain, improvement in metabolic profile, and CD4 count with insulin administration in an AIDS patient,” for a report of weight gain with daily subcutaneous insulin administration, which supports the idea that IPT could help patients gain weight, while simultaneously fighting tumors or infection.
As part of IPT cancer treatment, according to the 1992 patent, Dr. Perez Garcia 3 include substances like ascorbic acid (vitamin C) and magnesium bromide to stimulate the immune system and normalize the electrolytic balance of the body, typically deficient in magnesium in cases of cancer. These work together with the detoxification of the body, and the potentiation of anticancer drugs in the protocol.
Other vitamins and electrolytes are also administered, depending on the doctor’s judgment. Rapidly balancing the biochemistry in this way not only improves the health of the patient, but also apparently helps the body fight the tumors.
After an IPT treatment, patients are usually ravenously hungry. This is a great chance for them to eat heartily and gain the weight they need.
There is growing evidence that many or most cancers may have a hidden viral or even bacterial infection as the underlying cause. IPT has been shown to be extremely effective in treating and clearing both viral and bacterial infections, including those which are hidden in tissues and compartments of the body where normal drug treatment cannot effectively reach. Therefore it may be found to be advantageous to include antibiotic and antiviral drugs in many cancer IPT treatments, whether or not the underlying infectious agent is known. I call this multi-pathogen IPT (MP-IPT). (3/5/00)
It is certainly the position of IPTQ.org that IPT cancer research should be undertaken. Lots of it. We need to understand the mechanisms. We need to fine tune the IPT treatment system, and document it better. We need to see if the claims of the IPT doctors stand up in a larger clinical setting. And eventually, I suppose, IPT will make it to the Olympics of cancer research: multi-center multi-protocol clinical trials. Mark my prediction: If the IPT protocol in such a program is approved and overseen by a team of experienced IPT doctors, the experiment will be terminated for compassionate reasons after a few months when the better results of gentler IPT treatments become quite obvious.
In the mean time, patients who want this treatment now, can either go to doctors who are already trained and experienced in IPT, or can talk their own doctors into taking the training and giving this protocol a try.
We are talking about cancer here. One of the leading causes of death worldwide. It is expected to surpass heart disease as the leading cause of death in the United States, within this decade. And in the US, 20 million new cancer cases per year are expected by 2020. In China alone, 500,000 people die of lung cancer every year.
And we’re not just talking about cancer and people. We’re also talking about money. Michael Milken, in a recent talk in San Francisco, cited economists who calculated that the value of eliminating cancer would be $46 trillion. IPT will not eliminate cancer, but it appears to promise a gentler and more effective treatment for many types of cancer, with a higher rate of complete remissions. As such I can estimate that IPT for cancer is worth at least $5 trillion. So it seems to me that five million dollars invested in IPT research could yield results worth at least a thousand times more. (See my paper about this.) Low risk and high rewards. Who will take up this challenge?
In the developing world, people get cancer, too. But they do not have the luxury of abundant medical care, nor could they afford it. Expensive drugs, high-tech radiation, surgical suites, are all out of reach. I recently read that millions of poor people with cancer in the developing regions die in quiet agony, for lack of treatment, and for lack of pain medications. IPT could offer them a simple, inexpensive, low-tech therapy that uses a much smaller, and therefore more affordable, dose of chemotherapy drugs.
Information from Steven Ayre’s website: http://www.contemporarymedicine.net/;
Chemotherapy drugs are powerful cell-killing agents. In current medical practice, getting these drugs into the inside of cells where they do their work requires that they be administered in doses high enough to force them across the membranes of cancer cells.
A major drawback to this dosing strategy is a serious dose-related side effect profile frequently seen with anticancer drugs. This happens because chemotherapy agents do not discriminate between cancer cells and other normal cells in the patient’s body. They kill both kinds of cells, therefore there are side effects.
With recent advances in our understanding of the inner workings of cancer cells, it is now possible to avoid the dose-related side effects of chemotherapy, while at the same time increasing the effectiveness and specificity of these agents in killing cancer cells. The key to this is an innovative strategy for drug delivery called Insulin Potentiation Therapy (IPT).
Readers will recognize insulin as being the hormone used to treat diabetes. Secreted by the pancreas in healthy people, insulin is a powerful hormone with many actions in the human body, a principal one being to manage the delivery of glucose across cell membranes into cells. Insulin communicates its messages to cells by joining up with specific insulin receptors scattered on the outer surface of the cell membranes. Every cell in the human body has some of these receptors, with there being from one hundred to one hundred thousand of them per cell.
One might well ask, „What does any of this have to do with cancer cells?” It is a well-known scientific fact that cancer cells have a voracious appetite for glucose. Glucose is their unique source of energy, and because of the relatively inefficient way cancer cells burn this fuel, they use up a great deal of it. This is one reason why cancer patients lose so much weight. Because cancer cells require so much glucose, they virtually steal it away from the body’s normal cells, thus starving them.
The interesting connection between cancer cells and insulin is that recent findings published in the scientific medical literature report that cancer cells actually manufacture and secrete their own insulin. That cancer cells should be able to do this makes good sense, knowing of their requirements for large amounts of glucose to fuel their processes of uncontrolled growth. Related to this insulin secretion, and central to the operation of Insulin Potentiation Therapy, is the even more interesting fact that cancer cells have ten times more insulin receptors per cell than any of the normal cells in the body. This fact creates a valuable opportunity for the chemotherapy of cancer because it significantly differentiates normal cells from the cancerous ones.
Having ten times more insulin receptors than normal cells means that the effect of administered insulin will be ten times greater on cancer cells than on normal cells. With this difference, combined with actions of insulin in Insulin Potentiation Therapy, we are able to deliver an effective dose intensity of chemotherapy drugs to the inside of cancer cells – selectively, with a sparing of normal tissues – and this can be accomplished using greatly reduced doses of the drugs, effectively eliminating all their dose-related side effects.
There is a kind of poetic justice in this wonderful coincidence of cancer cell biology. The mechanisms that cancer cells use to kill people are the same ones manipulated in IPT to selectively potentiate chemotherapy effects in them, and to more safely and effectively kill the cancer cells. A published article about cancer cells in tissue culture reported that the addition of insulin to the culture medium enhanced the cell-killing effect of methotrexate – a commonly used chemotherapy drug – by a factor of up to ten thousand. This striking result was attributed to two effects on the cancer cells.
One was an effect of insulin to increase the trans-membrane transport of the methotrexate into the cell. The other was what the authors called „metabolic modification by insulin” within the cancer cells. There is yet another wonderful and powerful coincidence of cancer cell biology involved in this factor of „metabolic modification” – one that fits right in with the workings of Insulin Potentiation Therapy.
Just as cancer cells have their own independent secretion of insulin for unlimited access to the fuel they require, they also have their own independent secretion of something called insulin-like growth-factor to provide them with an unlimited stimulus for growth. Cancer cells also have ten times more of the receptors for insulin-like growth-factor on their cell membranes – just as for the insulin receptors.
The metabolic modification by insulin mentioned above results from the fact that not only can it join up with its own specific receptors on cell membranes, but insulin is also able to join up with the receptors for insulin-like growth-factor, and to communicate messages about growth to these cells. While it may seem highly undesirable for a cancer therapy to actually promote cancer cell growth, this is in fact a valuable effect of insulin here.
Chemotherapy side-effects result from actions on the cells of patient’s hair follicles, their bone marrow, and the cells lining the stomach and intestines. This is what causes the hair loss, low blood cell counts, and the nausea and vomiting. What these different cell types all have in common – along with cancer cells – is that they are all rapidly dividing cells.
Chemotherapy drugs like to attack rapidly dividing cells, indiscriminately. In a tumor, not all the cancer cells are in this rapidly dividing stage all at once. They take turns. When insulin joined up with the excess of insulin-like growth-factor receptors on those cancer cells in the tissue culture, it stimulated growth in many of the cells that were not in this growth phase.This „metabolic modification by insulin” rendered more of these cells susceptible to chemotherapy attack, contributing to their increased death rate as observed in the experiment.
In Insulin Potentiation Therapy, insulin administration does cause the blood glucose to go down. This is called hypoglycemia. This hypoglycemia is an anticipated side-effect of the insulin, one rapidly and effectively controllable with intravenous glucose infusions at an appropriate time, according to the IPT protocol. The principal role insulin plays in IPT is that ofa biologic response modifier. It modifies the biologic response of cancer cells in such a way that lowered doses of anticancer drugs, administered in conjunction with insulin, will kill the cancer cells more effectively. Insulin modifies the cell membrane allowing more anticancer drugs into the cell. It also modifies the growth characteristics in tumors making more of the cancer cells vulnerable to anticancer drug effects.
Due to the great excess of insulin-sensitive receptors on cancer cell membranes, we are now able to create a clear differentiation between cancer and normal cells using insulin.
Because of this important element of differentiation, along with the biologic response modification insulin produces, conventional chemotherapy drugs get targeted more specifically and more effectively inside the cancer cells only, and this can occur with the use of greatly reduced doses of these cell-killing drugs. Cancer cells die, tumors shrink, and no side-effects are caused in any other tissues. Insulin Potentiation Therapy appears to be a wonderful new way of treating cancer using nothing other than conventional chemotherapy drugs.
For more information, go to http://www.contemporarymedicine.net/ipt/ipt_main.shtml. For a list of doctors that use IPT, go to http://www.iptq.com. One pioneer of this therapy is Dr. Garcia – He has a clinic in Mexico.
|Articles – Published and unpublished IPT articles, scientific and popular.
|Documents – IPT protocols, historical documents, etc.
|Patents – Text of three US patents for insulin potentiation therapy (IPT).
|Bibliography – scientific papers that help support scientific understanding of IPT.
|Books – Three complete books about IPT. Tables of contents of others not yet scanned or translated.|
Publications and Essays on IPT
Blood Brain Barrier Passage of Azidothyumidine in Rats: Effects of Insulin – S.G. Ayre, B. Skaletski, A.D. Mosnaim. Research Communications in Chemical Pathology and Pharmacology. Jan. 1989. Vol. 63, No. 1.
Low dose chemotherapy in combination with insulin for the treatment of metastatic tumors: C. Damyanov, M. Radoslavova, V. Gavrilov, D. Stoeva. Medical Center of Integrative Medicine, Sofia, Bulgaria. Journal of BUON 14: 711-15, 2009.
Insulin Potentiation Therapy in the treatment of malignant neoplastic diseases: a three year study: Ch. Damyanov, MD, PhD, D. Gerasimova, MD, D. Stoeva, MD, D. Dyukmedzhieva, MD. Medical Center of Integrative Medicine, Sofia, Bulgaria.
Supportive Studies – Published clinical and in-vitro studies that support the use of insulin as a biologic response modifier.
Metabolic Modification by Insulin Enhances Methotrexate Cytotoxicity in MCF-7 Human Breast Cells. Alabaster, O. Vonderhaar, B. and Shafie, S. Eur J Cancer Clin Oncol. Vol 17, No. 11, pp 1223-1228. 1961.
Insulin treatment in cancer cachexia: effects on survival, metabolism, and
physical functioning. Lundholm K, Körner U, Gunnebo L, Sixt-Ammilon P, Fouladiun M, Daneryd P, Bosaeus I. Clin Cancer Res. 2007 May 1;13(9):2699 706.
Preclinical safety and antitumor efficacy of insulin combined with irradiation. Bénédicte F. Jordan, Nelson Beghein, Nathalie Crokart, Christine Baudelet, Vincent Gregoire, Bernard Gallez. Radiotherapy and Oncology 81 (2006) 112–117.
Insulin-induced enhancement of antitumoral response to methotrexate in breast cancer patients. Lasalvio-Prisco, Eduardo, et.al. Cancer Chemother Pharmacol (2004) 53: 220–224.
Periodical Publications on Dr. Ayre and IPT
History of IPT
Documents of Historical Interest
- 1937 Austin State Hospital Pilot Study
- Comments of Mexican Military on IPT – Letter One – July 1, 1939
- Comments of Mexican Military on IPT – Letter Two – September 21, 1939
- Insulin For Everything – Time Magazine 1944
Personal Essays from Dr. Ayre
Best of health!